Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
2,551
datasets available to search
ShareScore release 0.9.0
Dataset results
2,551 results for “complication”
Data of top 50 most cited articles about COVID-19 and the complications of COVID-19
Open the record for dataset details and reuse information.
Staggering Sugammadex for Reduction of Postoperative Complications: A Randomized Controlled Trial
<p><strong>Background:</strong> We investigated if staggering sugammadex would reduce postoperative complications(with special regards to cough), compared to single dose of sugammadex or standard neostigmine in patients undergoing thyroidectomy surgery.</p> <p><strong>Methods</strong>: A 36 adult patients aged 21-60 years old, ASA I and II undergoing thyroidectomy surgery, were randomized into 3 groups; (S group) that received 2 mg/kg sugammadex as single bolus, (SS group) that received sugammadex 2 mg/kg in a staggered dose of 1 mg/kg prior to extubation and another 1 mg/kg immediately after extubation and (N group) that received 0.05 mg/kg neostigmine combined with 0.02 mg/kg atropine.</p> <p><strong>Results</strong>: Cough was absent in (SS) group. The percent of cough was 33% in S group and about 67 % in N group.Patients of (SS) and (S) groups had significant shorter recovery time and extubation time. Patients of (N) group showed significant increase in HR and SBP at 5 min after reversal compared to both (SS) and (S) groups, but no significant difference in DBP between all groups. There was no significant difference between all groups regarding postoperative complications other than cough.</p> <p><strong>Conclusion: </strong>Staggered sugammadex reduces significantly risks for cough on emergence when compared to 2mg single bolus sugammadex .In addition, staggered sugammadex-as well as bolus sugammadex-has better recovery and more stable hemodynamics when compared to neostigmine.</p>
Neurologic complications of COVID-19
<p><span><span><b>Objective:</b> The SARS-Cov2 virus is protean in its manifestations, affecting nearly every organ system. However, nervous system involvement and its impact on disease outcome are poorly characterized. The objective of the study is to determine if neurological syndromes are associated with increased risk of inpatient mortality.</span></span></p> <p><span><span><b>Methods:</b> 581 hospitalized patients with confirmed SARS-Cov2 infection, neurological involvement and brain-imaging were compared to hospitalized non-neurological COVID-19 patients. Four patterns of neurological manifestations were identified –acute stroke, new or recrudescent seizures, altered mentation with normal imaging, and neuro-COVID-19 complex. Factors present on admission were analyzed as potential predictors of in-hospital mortality, including sociodemographic variables, pre-existing comorbidities, vital-signs, laboratory values, and pattern of neurological manifestations. Significant predictors were incorporated into a disease-severity score. Patients with neurological manifestations were matched with patients of the same age and disease severity to assess the risk of mortality. </span></span></p> <p><span><span><b>Results:</b> 4711 patients with confirmed SARS-Cov2 infection were admitted to one medical system in New York City during a 6-week period. Of these, 581 (12%) had neurological issues of sufficient concern to warrant neuro-imaging. These patients were compared to 1743 non-neurological COVID-19 patients matched for age and disease-severity admitted during the same period. Patients with altered mentation (n=258, p =0.04, OR 1.39, CI 1.04 – 1.86) or radiologically confirmed stroke (n=55, p = 0.001, OR 3.1, CI 1.65-5.92) had a higher risk of mortality than age and severity-matched controls. </span></span></p> <p><span><span><b>Conclusions:</b> The incidence of altered mentation or stroke on admission predicts a modest but significantly higher risk of in-hospital mortality independent of disease severity. While other biomarker factors also predict mortality, measures to identify and treat such patients may be important in reducing overall mortality of COVID-19. </span></span></p>
Data from: Clinical complications and outcomes of angiographically negative subarachnoid hemorrhage
Objective: To define the in-hospital course, complications, short- and long-term functional outcomes of patients with angiographically negative subarachnoid hemorrhage (anSAH), particularly those with aneurysmal-pattern anSAH (aanSAH). Methods: Retrospective cohort study of patients with aneurysmal subarachnoid hemorrhage (aSAH), aanSAH and perimesencephalic-pattern anSAH (panSAH) treated at a single tertiary referral center between January 2006 and April 2018. Ninety-nine patients with anSAH (33 aanSAH and 66 panSAH) and 464 patients with aSAH were included in this study. Outcomes included symptomatic hydrocephalus requiring CSF drainage, need for ventriculoperitoneal shunt (VPS), radiographic vasospasm, delayed cerebral ischemia (DCI), radiographic infarction, disability level within one year of ictus and at last clinical follow-up as defined by modified Rankin Scale (mRS). Results: Patients with aanSAH and panSAH had similar rates of DCI and radiologic infarction, and patients with aanSAH had significantly lower rates compared to aSAH (P≤0.018). Patients with aanSAH were more likely than those with panSAH to require temporary CSF diversion and VPS (P≤0.03), with similar rates to those seen in aSAH. Only one patient with anSAH died in the hospital. Compared to those with aSAH, patients with aanSAH were significantly less likely to have a poor functional outcome within one year of ictus (OR 0.26, 95% CI 0.090 – 0.75) and at last follow-up (HR 0.30, 95% CI 0.19 – 0.49, P=0.002). Conclusions: DCI is very uncommon in anSAH, but patients with aanSAH have a similar need for short- and long-term CSF diversion to patients with aSAH. Nevertheless, patients with aanSAH have significantly better short- and long-term outcomes.
Data from: Urgent-start peritoneal dialysis and hemodialysis in ESRD patients: complications and outcomes
Background: Several studies have suggested that urgent-start peritoneal dialysis (PD) is a feasible alternative to hemodialysis (HD) in patients with end-stage renal disease (ESRD), but the impact of the dialysis modality on outcome, especially on short-term complications, in urgent-start dialysis has not been directly evaluated. The aim of the current study was to compare the complications and outcomes of PD and HD in urgent-start dialysis ESRD patients. Methods: In this retrospective study, ESRD patients who initiated dialysis urgently without a pre-established functional vascular access or PD catheter at a single center from January 2013 to December 2014 were included. Patients were grouped according to their dialysis modality (PD and HD). Each patient was followed for at least 30 days after catheter insertion (until January 2016). Dialysis-related complications and patient survival were compared between the two groups. Results: Our study enrolled 178 patients (56.2% male), of whom 96 and 82 patients were in the PD and HD groups, respectively. Compared with HD patients, PD patients had more cardiovascular disease, less heart failure, higher levels of serum potassium, hemoglobin, serum albumin, serum pre-albumin, and lower levels of brain natriuretic peptide. There were no significant differences in gender, age, use of steroids, early referral to a nephrologist, prevalence of primary renal diseases, prevalence of co-morbidities, and other laboratory characteristics between the groups. The incidence of dialysis-related complications during the first 30 days was significantly higher in HD than PD patients. HD patients had a significantly higher probability of bacteremia compared to PD patients. HD was an independent predictor of short-term (30-day) dialysis-related complications. There was no significant difference between PD and HD patients with respect to patient survival rate. Conclusion: In an experienced center, PD is a safe and feasible dialysis alternative to HD for ESRD patients with an urgent need for dialysis.
CURRENT APPROACHES TO TREATMENT OF CHRONIC KIDNEY DISEASE COMPLICATED NEPHROGENIC HYPERTENSION
Open the record for dataset details and reuse information.
COMPARATIVE EVALUATION OF COMPLICATIONS OF DIABETES MELLITUS - NEUROPATHY AND ANGIOPATHY
Open the record for dataset details and reuse information.
WAYS TO IMPROVE DIAPEUTICA METHODS AND X-RAY SURGERY IN THE TREATMENT OF COMPLICATED FORMS OF CHOLESTILIS DISEASE
Open the record for dataset details and reuse information.
PRINCIPLES OF SURGICAL TREATMENT FOR COMPLICATED CHOLECYSTITIS
Open the record for dataset details and reuse information.
SURGICAL ASSISTANCE IN THE TREATMENT OF COMPLICATED FORMS OF CHOLELITHIS DISEASES
Open the record for dataset details and reuse information.
THE BENEFITS OF X-RAY SURGERY IN THE TREATMENT OF COMPLICATED FORMS OF CALLSTONIS DISEASE
Open the record for dataset details and reuse information.
OPTIMIZATION OF DIAPEUTICA METHODS AND X-RAY SURGERY IN THE TREATMENT OF COMPLICATED FORMS OF CELLOLSTONIS DISEASE
Open the record for dataset details and reuse information.
VASCULAR ENDOTHELIAL MULTICATTOCHLAP IN PATIENTS WITH PURULENT-NECROTIC COMPLICATIONS OF DIABETIC HEEL SYNDROME
Open the record for dataset details and reuse information.
SPECIFICITY OF TREATMENT IN PATIENTS WITH PURULENT-NECROTIC COMPLICATIONS OF DIABETIC HEEL SYNDROME
Open the record for dataset details and reuse information.
DIFFERENTIATED APPROACHES TO THE TREATMENT OF ATOPIC DERMATITIS COMPLICATED BY BACTERIAL, FUNGAL AND VIRAL INFECTION
Open the record for dataset details and reuse information.
MICROFLORA ANALYSIS OF OSTEOMYELITIS AND OSTEOARTHRITIS IN PATIENTS WITH COMPLICATED FORM OF DIABETIC FOOT SYNDROME
Open the record for dataset details and reuse information.
COMPARATIVE EVALUATION OF COMPLICATIONS OF DIABETES MELLITUS - NEUROPATHY AND ANGIOPATHY.
Open the record for dataset details and reuse information.
FIGURE 21 in Revision of the genus Centrophorus (Squaliformes: Centrophoridae): Part 3-Redescription of Centrophorus uyato (Rafinesque) with a discussion of its complicated nomenclatural history
FIGURE 21. Large catches of Centrophorus uyato off Mallorca, Spain, in 1995.
FIGURE 1 in Revision of the genus Centrophorus (Squaliformes: Centrophoridae): Part 3-Redescription of Centrophorus uyato (Rafinesque) with a discussion of its complicated nomenclatural history
FIGURE 1. Original illustration of Squalus uyatus in Rafinesque (1810) from off Sicily, Italy.
FIGURE 3 in Revision of the genus Centrophorus (Squaliformes: Centrophoridae): Part 3-Redescription of Centrophorus uyato (Rafinesque) with a discussion of its complicated nomenclatural history
FIGURE 3. Illustration of Centrophorus granulosus in Müller & Henle (1839).
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.